FDA Moves Blood Test Device Into Class II
Published Date: 6/1/2026
Rule
Summary
The FDA is officially putting the von Willebrand factor assay into Class II, meaning it now has special safety rules but fewer red tape hurdles. This change helps labs and patients get access to this important blood test faster and safer, starting June 1, 2026. If you make or use these devices, expect smoother approvals and no big cost jumps.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Easier Approval Path for Test Makers
The FDA officially classified the von Willebrand factor assay as Class II with special controls effective June 1, 2026 (classification applicable September 29, 2022). That classification lets this device serve as a predicate for future devices so sponsors can use the less burdensome 510(k) premarket notification process instead of a De Novo request or premarket approval.
Faster, Safer Patient Access to Test
FDA says classifying the von Willebrand factor assay into Class II will provide a reasonable assurance of safety and effectiveness and will enhance patients' access to beneficial innovation, in part by reducing regulatory burdens; the order is effective June 1, 2026 (classification applicable September 29, 2022). The device is a prescription test intended to aid diagnosis and management of von Willebrand factor disorders.
New Test Makers Must Meet Specific Study and Label Rules
Manufacturers marketing a von Willebrand factor assay must meet special controls that include detailed design verification and validation (analytical performance such as precision, linearity, detection capability, specimen/reagent stability, and hook effect), clinical comparison studies using representative clinical samples conducted at a minimum of three external sites, pediatric validation when applicable, and labeling that identifies known interferents and summarizes performance. The device remains prescription-only and is subject to premarket notification under section 510(k).
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073 — Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-14155 — Considerations for Potential Future Therapeutic Use of Psychedelic Drugs; Public Hearing; Request for Comments
The FDA is hosting a public hearing on September 14, 2026, to explore how psychedelic drugs might be used safely as future medicines. They want to hear from patients, doctors, and anyone interested before October 5, 2026, to help shape rules and support safe, supervised treatments. This could change how some mental health conditions are treated and might open new doors for therapy options.
2026-14158 — Psychedelic Drugs: Considerations for Clinical Investigations; Guidance for Industry; Availability
The FDA just released new guidance to help drug makers design safe and smart clinical trials for psychedelic medicines, which could treat mental health and addiction issues. This update affects companies developing these drugs by giving clear rules to follow, speeding up research while keeping safety first. The guidance is effective now, and the FDA welcomes comments anytime, making it easier and clearer to bring these promising treatments to patients.
2026-14119 — Topical Dermatologic Corticosteroids: In Vivo Bioequivalence; Guidance for Industry; Availability
The FDA just released new rules for companies making generic skin creams with steroids. These rules explain how to prove their products work just as well as the original ones by testing on real people’s skin. This update affects drug makers and helps speed up safe, affordable medicine options starting now.
2026-13820 — Determination That TOVALT ODT (Zolpidem Tartrate) Orally Disintegrating Tablets, 5 Milligrams and 10 Milligrams, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that TOVALT ODT tablets (5 mg and 10 mg) weren’t taken off the market because of safety or effectiveness problems. This means generic drug makers can now apply to sell their own versions, making it easier and cheaper for people who need this sleep aid. If approved, more affordable options could hit the shelves soon, helping patients and saving money.
Previous / Next Documents
Previous: 2026-10896 — Standard Instrument Approach Procedures, and Takeoff Minimums and Obstacle Departure Procedures; Miscellaneous Amendments
Starting June 1, 2026, the FAA is updating how pilots approach and take off from certain airports to keep flights safe and smooth. These changes include new rules for landing and takeoff paths because of new tech, obstacles, or air traffic needs. Pilots and airports affected should check the updated procedures online—no extra costs, just safer skies!
Next: 2026-10899 — Medical Devices; Dental Devices; Classification of the Intraoral Cooling Device
The FDA is officially putting the intraoral cooling device into class II, meaning it has special safety rules but fewer hurdles than the highest-risk devices. This change helps make sure the device is safe and effective while making it easier for patients to get this cool tech. The new classification is effective June 1, 2026, but it’s been in place since October 14, 2022, so manufacturers can plan ahead without extra costs.